GalNAc-T14 Antibody (A-8): sc-393051

GalNAc-T14 Antibody (A-8) is a mouse monoclonal IgG2a kappa light chain antibody that detects GalNAc-T14 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). GalNAc-T14 (A-8) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. GalNAc-T14, also known as UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 14, plays a crucial role in initiating mucin-type O-linked glycosylation, a process vital for protein stability, cell signaling, and protective mucosal barrier formation. This 552 amino acid single-pass type II membrane protein is primarily localized in the Golgi apparatus, where GalNAc-T14 utilizes calcium and manganese as cofactors to transfer N-acetylgalactosamine to serine and threonine residues on target proteins. A Ricin B-type lectin domain in GalNAc-T14′s structure suggests specific interaction with carbohydrate moieties, essential for substrate specificity. GalNAc-T14 is highly expressed in fetal and adult kidney tissues and exists in multiple alternatively spliced isoforms, highlighting GalNAc-T14′s importance in developmental processes and potential implications in kidney function and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

GalNAc-T14 Antibody (A-8) References:

1. The acceptor specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases.  |  Elhammer, AP., et al. 1999. Glycoconj J. 16: 171-80. PMID: 10612416
2. Cloning and characterization of a novel UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, pp-GalNAc-T14.  |  Wang, H., et al. 2003. Biochem Biophys Res Commun. 300: 738-44. PMID: 12507512
3. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases.  |  Ten Hagen, KG., et al. 2003. Glycobiology. 13: 1R-16R. PMID: 12634319
4. N-Acetylgalactosaminyltransferase 14, a novel insulin-like growth factor binding protein-3 binding partner.  |  Wu, C., et al. 2007. Biochem Biophys Res Commun. 357: 360-5. PMID: 17434446
5. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.  |  Wagner, KW., et al. 2007. Nat Med. 13: 1070-7. PMID: 17767167
6. GalNAc-T14 may be involved in regulating the apoptotic action of IGFBP-3.  |  Wu, C., et al. 2009. J Biosci. 34: 389-95. PMID: 19805900
7. GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.  |  Kwon, OS., et al. 2015. Oncotarget. 6: 41916-28. PMID: 26544896
8. GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma.  |  Tsou, YK., et al. 2017. Oncotarget. 8: 29151-29160. PMID: 28418863
9. GalNAc-T14 may Contribute to Production of Galactose-Deficient Immunoglobulin A1, the Main Autoantigen in IgA Nephropathy.  |  Jemelkova, J., et al. 2023. Kidney Int Rep. 8: 1068-1075. PMID: 37180502
10. GalNAc-T14 may be involved in regulating the apoptotic action of IGFBP-3  |  Chen Wu, et al. 2009. Springer Nature. 34: 389-395.
11. A validated collection of mouse monoclonal antibodies to human glycosyltransferases functioning in mucin-type O-glycosylation  |  Catharina Steentoft, et al. 2019. Glyvobiology. 29: 645-656.
12. GalNAc-T14 may Contribute to Production of Galactose-Deficient Immunoglobulin A1, the Main Autoantigen in IgA Nephropathy  |  Jana Jemelkova, et al. 2023. ELSEVIER. 8: 1068-1075.

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-GalNAc-T14 Antibody (A-8) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-GalNAc-T14 Antibody (A-8) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

GalNAc-T14 Antibody (A-8) Specifications

Alternate Product Name: GalNAc-T14

Product Clone Name: A-8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 411-552

Epitope Target: GalNAc-T14

Epitope Species: human

Product Reactivity/Detection: GalNAc-T14

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for GalNAc-T14 Antibody (A-8): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin